TMCnet News

ABL Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease
[September 21, 2016]

ABL Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease

ABL, Inc. (ABL), a global contract research and manufacturing service provider to the U.S. Government and biopharmaceutical industry, announced today it is one of four prime contractors awarded a ten-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSN272201600004I "Preclinical Services for Biopharmaceutical Product Development" by the Division of Microbiology and Infectious Diseases (DMID) within the National Institute of Allergy and Infectious Disease (NIAID).

The contract is part of a multiple award ID/IQ pool with a maximum ceiling of $159,444,814 to provide biopharmaceutical product development services for a wide range of critical global infectious disease issues including development of products against bioterrorism, drug resistance, emerging and re-emerging pathogens, and infectious diseases in developing areas of the world. ABL will provide NIAID with a comprehensive portfolio of services including product development planning, process and bioanalytical assay development, cGMP manufacturing and release of drug product, and regulatory support for promising biopharmaceutical therapeutics and diagnostis leading to Investigational New Drug (IND) applications, Biologics License Applications (BLA) or other FDA submissions.

"This award expands ABL's support of DMID's vital gap-filling product development programs that are crucial to tackling some of the most urgent global public health issues we face today," explains Dr. Thomas VanCott, President and CEO of ABL. "From food borne pathogens like Shigella, to emerging disease agents like Ebola and Zika viruses, ABL continues to put its significant infectious disease resources to work helping advance novel therapies and diagnostics into the clinic and beyond."

About ABL

ABL, Inc. is a global biomedical contract research and manufacturing organization dedicated to advancing therapeutics, vaccines and other biologic products. ABL has extensive experience working with diverse organizations including industry, government and academic entities. ABL maintains GMP facilities meeting U.S. and European regulatory standards, providing process and assay development, cGMP manufacturing of bulk drug substance, cGMP aseptic fill and finish of drug product, and QC bioanalytical testing. Our U.S. and European immunological and molecular laboratories support clients' preclinical and GCLP clinical sample processing and testing needs. ABL is a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally.

For more information visit or contact us.

[ Back To's Homepage ]